GlaxoSmithKline Pakistan (KAR:GLAXO) Ending Cash Position : ₨6,188 Mil (As of Mar. 2025)

View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan Ending Cash Position?

GlaxoSmithKline Pakistan's Ending Cash Position for the quarter that ended in Mar. 2025 was ₨6,188 Mil.

GlaxoSmithKline Pakistan's quarterly Ending Cash Position declined from Sep. 2024 (₨6,693 Mil) to Dec. 2024 (₨6,513 Mil) and declined from Dec. 2024 (₨6,513 Mil) to Mar. 2025 (₨6,188 Mil).

GlaxoSmithKline Pakistan's annual Ending Cash Position declined from Dec. 2022 (₨4,470 Mil) to Dec. 2023 (₨3,611 Mil) but then increased from Dec. 2023 (₨3,611 Mil) to Dec. 2024 (₨6,513 Mil).

GlaxoSmithKline Pakistan Ending Cash Position Historical Data

The historical data trend for GlaxoSmithKline Pakistan's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pakistan Ending Cash Position Chart

GlaxoSmithKline Pakistan Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

5,720.50

8,482.77

4,470.38

3,610.76

6,513.45

GlaxoSmithKline Pakistan Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															3,073.03	4,470.33	6,693.04	6,513.45	6,187.57

GlaxoSmithKline Pakistan Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

GlaxoSmithKline Pakistan's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	3610.757	+	2902.69
	=	6,513

GlaxoSmithKline Pakistan's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	6513.447	+	-325.88
	=	6,188

GlaxoSmithKline Pakistan Ending Cash Position Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pakistan's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Pakistan Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

35, Dockyard Road, West Wharf, Karachi, PAK, 74000

Website

https://www.pk.gsk.com

GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines